A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort Turbuhaler+ Bricasol pMDI Compared With Pulmicort Turbuhaler+Bricasol pMDI in Chinese Patients With COPD
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 25 Feb 2008 Status change from in progress to completed, as reported by clinicaltrials.gov.
- 11 Jan 2008 The expected completion date for this trial is now 1 Jan 2008.
- 26 Jul 2007 Status changed from recruiting to in progress.